Membranoproliferative Glomerulonephritis

• CLINICAL_TRIALS research · 2026-03-23
  Clinical Trial Update: New Analytic Tools for aHUS and C3G Diagnosis [NA]

  An active-not-recruiting trial from Mario Negri Institute is evaluating new analytic tools to improve the diagnosis of atypical hemolytic ur…

• CLINICAL_TRIALS research · 2026-03-23
  Clinical Trial Update: Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases [NA]

  This clinical trial update describes a project to develop RNA-Seq as a complementary diagnostic tool for rare diseases, with recruitment ong…

• CLINICAL_TRIALS approval · 2025-11-06
  Clinical Trial Update: C3G/Primary IC-MPGN EAP

  Apellis' pegylated C3 inhibitor pegcetacoplan has gained marketing approval for C3 glomerulopathy and immune complex–mediated MPGN as part o…

• CLINICAL_TRIALS trial_result · 2025-08-06
  Clinical Trial Update: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]

  Phase 3 trial evaluating pegcetacoplan for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis has completed with …

• CLINICAL_TRIALS research · 2025-06-22
  Clinical Trial Update: Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy [Phase 2]

  Phase 2 trial evaluating aliskiren (a renin inhibitor) versus enalapril in C3 glomerulopathy and related glomerulonephritis, currently recru…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-02-07
  Clinical Trial Update: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN [Phase 2]

  Phase 2 trial assessing pegcetacoplan for post-transplant recurrence of C3 glomerulopathy and immune complex-mediated MPGN has completed wit…

• CLINICAL_TRIALS trial_result · 2021-07-16
  Clinical Trial Update: Daratumumab in Treatment of PGNMID and C3 GN [Phase 2]

  Phase 2 trial update for daratumumab in membranoproliferative glomerulonephritis showing completed status with results posted.

• CLINICAL_TRIALS trial_result · 2019-02-19
  Clinical Trial Update: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy [Phase 1]

  A Phase 1 trial evaluating eculizumab for dense deposit disease and C3 nephropathy has completed, with results posted in 2019.

• CLINICAL_TRIALS trial_result · 2018-01-17
  Clinical Trial Update: Eculizumab in Primary MPGN [Phase 2]

  Phase 2 trial update for eculizumab in membranoproliferative glomerulonephritis has completed.

• CLINICAL_TRIALS trial_result · 2017-06-16
  Clinical Trial Update: Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis [Phase 3]

  Phase 3 clinical trial update evaluating rituximab for membranoproliferative glomerulonephritis.

• CLINICAL_TRIALS trial_result · 2013-01-16
  Clinical Trial Update: Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis [Phase 1]

  Phase 1 pilot study evaluating rituximab for membranoproliferative glomerulonephritis has completed.

• CLINICAL_TRIALS trial_result · 2008-03-04
  Clinical Trial Update: BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis [Phase 2]

  A Phase 2 clinical trial of BG9588, an anti-CD40L antibody, for lupus nephritis has completed.